Investigating the T1D Increase: A Look at Rising Rates in Children Amid COVID-19

Host: John Buse, MD, PhD
Guest: Mary de Groot, PhD

The prevalence of diabetes-related stigma is alarmingly high. In fact, four in five adults have reported experiencing some form of diabetes stigma at some point in their lives. To learn how we as healthcare providers can help reduce this burden for our patients with diabetes, Dr. John Buse speaks with Dr. Mary de Groot, Professor of Medicine and the Associate Vice Chair for Wellness at Indiana University School of Medicine.

Host: Stuart Weinzimer, MD

The artificial pancreas represents the integration of two separate devices: a continuous glucose monitor and an insulin pump. Learn more about this technology and how it can help improve diabetic patients’ quality of life with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

Host: Stuart Weinzimer, MD

From continuous glocuose monitors to insulin pumps, there have been immense technological advancements for patients with type 1 diabetes. Learn more about how these two tools can be used to treat pediatric patients with type 1 diabetes with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

Host: John Buse, MD, PhD
Guest: Michael Fang, PhD

According to a recent study published in the Annals of Internal Medicine, the median age of patients with type 1 diabetes is 24. However, type 1 diabetes that develops in adulthood is often mistakenly identified as type 2 diabetes, resulting in improper treatment. Joining Dr. John Buse to review this study’s key findings and how we can determine if an adult with new-onset diabetes might have type 1 diabetes is Dr. Michael Fang, Assistant Professor in the Division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University.

Host: John Buse, MD, PhD
Guest: Maria Jose Redondo, MD, PhD, MPH

A recent paper focused on a variety of topics associated with type 1 diabetes, including its heterogenenity, endotypes, slowly progressive insulin-dependent diabetes, and the term type 1.5 diabetes. Dive into these topics with Dr. John Buse and Dr. Maria Redondo, Professor of Pediatrics in the Division of Pediatric Diabetes and Endocrinology at Baylor College of Medicine in Texas.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: David Selzer, MD

New research suggests that a GLP-1 receptor agonist medication, semaglutide, which has been approved for type 2 diabetes and obesity, could also be used to treat type 1 diabetes in patients. So what are the risks for patients who have type 1 diabetes and who are obese? Joining Dr. Mary Katherine Cheeley to discuss this is Dr. David Selzer, Clinical Instructor of Medicine at NYU Grossman School of Medicine and leads the Medical Weight Loss Program at NYU Langone Medical Associates in the Florida Division.

Host: John Buse, MD, PhD
Guest: Helen Murphy, PhD

There are many challenges associated with managing type 1 diabetes (T1D) in pregnant patients, which is why a recent study examined the use of an automated insulin delivery system in this patient population. Using this method, insulin doses were adjusted every 8 to 10 minutes according to a patient’s real-time glucose levels taken from her continuous glucose monitor. As a result, women experienced a higher percentage time in the pregnancy glucose target range, less hyperglycemia, and less gestational weight gain. Learn more about how these findings may impact the management of T1D both during and after pregnancy with Dr. John Buse and Dr. Helen Murphy, a Professor of Medicine in Diabetes and Antenatal Care at the University of East Anglia in the United Kingdom.

Host: John Buse, MD, PhD
Guest: Beth Pyatak, PhD, OTR/L

According to a recent study, fluncuations in glucose levels while sleeping can directly impact type 1 diabetes patients’ ability to complete daily activities. In fact, it was found that higher variability overnight led to lower sustained attention and lower engagement in demanding activities the following day. So how can we control glucose levels to help our patients feel better? Explore the study’s key findings and management strategies with Dr. John Buse and Dr. Elizabeth Pyatak, an Associate Professor of Occupational Science and Occupational Therapy at the University of Southern California who worked on the study.

Host: John Buse, MD, PhD
Guest: Simon Heller, MD

Amid the crisis around the cost of diabetes care worldwide, biosimilar insulins could help save millions of dollars and allow more patients to be treated safely and effectively. But how exactly are these products approved, and how do they compare to the original product? Find out with Dr. John Buse and Dr. Simon Heller, Professor of Clinical Diabetes at the University of Sheffield and the Director of Research and Development at Sheffield Teaching Hospitals Foundation Trust in the United Kingdom. Together, they’ll review Dr. Heller’s recent paper on biosimilar basal insulins that was published in Clinical Diabetes.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Elizabeth Cook, PharmD, AE-C, BCACP, CDCES

With a shortage of insulin products in the United States, our diabetic patients are left without lifesaving medications, making this a prominent barrier in clinical practice. However, insulin biosimilars may offer more accessibility and affordability, but what do we know about them? Join Dr. Mary Katherine Cheeley as she speaks with Dr. Lizzie Cook, Clinical Pharmacist at Robert J. Dole Veteran Affairs Medical Center in Wichita, Kansas.